معرفی
Michael A. Barry, Ph.D., is a Professor of Medicine at Mayo Clinic in Rochester, Minnesota, where he holds primary and joint appointments as a Consultant in the Department of Internal Medicine (Division of Infectious Diseases), Department of Immunology, and Department of Molecular Medicine. He leads the Virology, Vector and Vaccine Engineering Laboratory, focusing on developing advanced gene therapies, viral vectors, and vaccines for challenging diseases.
- Institution: Mayo Clinic
- School: College of Medicine and Science
- Department: Department of Internal Medicine
- Academic Rank: Professor
- Email: barry.michael@mayo.edu
Education:
- Ph.D., Pharmacology and Toxicology, Dartmouth College
- Postgraduate Trainee, University of Texas Southwestern Medical Center
- B.S., Chemistry, Nebraska Wesleyan University
Dr. Barry’s research centers on virology, gene therapy, and vaccine engineering. His lab develops in vivo molecular and viral therapies using adenovirus, adeno-associated virus (AAV), and lipid nanoparticles. Key areas include gene therapy for metabolic diseases like propionic acidemia and Alport syndrome, gene-based vaccines for HIV, influenza, Zika, and SARS-CoV-2, and oncolytic immunotherapy viruses for cancer. His team engineered a single-cycle adenovirus COVID-19 vaccine tested in Phase 1 trials (NCT04839042) and is advancing CRAd657-CD40L for melanoma clinical trials in 2025. They also work on basic virology of Ebola and pandemic influenza, leveraging findings for therapeutic development.
His recent publications highlight innovations in adenoviral vector generation (FastAd toolkit), mucosal vaccine delivery, structural insights into adenovirus-blood interactions, and AAV-mediated therapies for musculoskeletal and gastrointestinal conditions. These works reflect a strong trend in translational virology and targeted therapeutics.
Scientific Awards:
None explicitly mentioned in the provided text.
Advising and Grants:
Dr. Barry has secured substantial grant funding, including from the National Institute of Allergy and Infectious Diseases (NIAID) and Congressionally Directed Medical Research Programs, for projects such as single-cycle SARS-CoV-2 vaccines, oncolytic therapies for kidney cancer, Ebola virus pathogenesis, mucosal HIV vaccines, and Zika virus vaccines. He mentors trainees and supports postdoctoral fellowships, though specific student names are not listed. His lab fosters collaboration across Mayo Clinic centers, including the Center for Individualized Medicine, Center for Regenerative Biotherapeutics, and Mayo Clinic Comprehensive Cancer Center.
Labs and Teams:
He directs the Virology, Vector and Vaccine Engineering Laboratory, which focuses on cell-targeted delivery, vector purification, mucosal vaccination, polymer shielding of vectors, and optical imaging for tracking. The lab employs high-throughput screening, genetic engineering, and animal imaging to optimize vector specificity and reduce off-target effects.
